VEENENDAAL, Netherlands, Dec. 1 /PRNewswire/ -- Nucletron BV announces
that it has received FDA clearance to begin marketing its new Inverse
Treatment Planning software on the PLATO radiotherapy treatment planning
system.
Now, inverse treatment planning can be done in minutes not hours.
Nucletron's PLATO ITP software provides a new break-through in providing the
first fast inverse planning system that is integrated into a fully featured
three dimensional planning system.
PLATOcomplete(TM) (http://www.platocomplete.com) is now Nucletron's most complete
treatment planning system. "New software releases have made dramatic changes
that are important to our customers," said Tim Bateman, PLATO product manager.
"Extended functionality and a unique system-unified user interface now add to
Nucletron's well-established reputation as the first name in brachytherapy and
a pioneer in RTP systems."
Inverse treatment planning is the essential first step in being able to
deliver Intensity Modulation Radiation Therapy (IMRT) with modern medical
linear accelerators, and is designed to optimize radiation delivered to a
tumor while minimizing the potentially harmful radiation absorbed by healthy
organs.
"The improved normal tissue sparing capabilities of IMRT are especially
meaningful in our practice. Our positive experience as a member of
Nucletron's IMRT Collaboration Group has given us confidence that PLATO will
provide the means to effectively plan for IMRT," said Robert S. Lavey, M.D.,
M.P.H., Head, Radiation Oncology Program, Children's Hospital, Los Angeles, CA
With Nucletron's PLATO ITP inverse planning software, the radiation
oncologist defines the dose to be given to the tumor as well as the allowable
doses to surrounding healthy organs. The software then calculates the required
radiation beam intensity required to deliver an optimized radiation dose
distribution in the patient. The resulting treatment plan is then directly
downloaded to any of the treatment delivery systems now capable of IMRT with
multi-leaf collimators.
PLATO ITP can alternatively calculate the thickness of custom-made
filters, known as compensators, that also "modulate" the beam intensity. This
feature permits the advanced IMRT treatments to be given using conventional
treatment machines that are much more commonly used in radiation therapy
departments.
Based on an established algorithm by Thomas Bortfeld of the German Cancer
Research Center, DKFZ, in Heidelberg, PLATO ITP has been designed in
collaboration with major cancer treatment centers in the United States and
Europe. The interaction between the radiation oncologist and the software has
been carefully tailored to give the user advanced controls of the dose
distribution to be achieved, and the speed of the optimization allows the
results to be available in minutes.
PLATO ITP is the latest addition to the radiation therapy planning system
PLATOcomplete, that provides comprehensive planning tools for both
brachytherapy and external beam radiation therapy.
Nucletron B.V., with headquarters in Veenendaal, The Netherlands, is a
worldwide leader in radiotherapy systems, and specializes in some of the most
innovative products used for cancer treatment. The company has 11 offices
worldwide, including its corporate headquarters in the Netherlands. Nucletron
is the world leader in remote afterloading brachytherapy, supplying the
majority of all systems worldwide. Nucletron B.V. is a subsidiary of Delft
Instruments, an international group of companies with some 1100 employees and
annual sales of almost NLG 400 million. The Nucletron's website address is
http://www.nucletron.com
SOURCE Nucletron BV
 back to top
Related links:
http://www.nucletron.com
CONTACT:
C. Cadel of Nucletron, +31-318-557-133
|
